Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  667, L.P.
2. Date of Event Requiring Statement (Month/Day/Year)
05/17/2013
3. Issuer Name and Ticker or Trading Symbol
SEATTLE GENETICS INC /WA [SGEN]
(Last)
(First)
(Middle)
667 MADISON AVENUE 21ST FLOOR
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEW YORK, NY US 10065
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,868,576 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Options (right to buy)These non-qualifie 05/17/2004 05/17/2014 Common Stock 10,000 $ 7.26 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/13/2005 05/12/2015 Common Stock 10,000 $ 5.11 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/19/2006 05/18/2016 Common Stock 10,000 $ 4.18 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/25/2007 05/25/2017 Common Stock 10,000 $ 10.2 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/16/2008 05/16/2018 Common Stock 10,000 $ 10.08 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/15/2009 05/15/2019 Common Stock 10,000 $ 8.38 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/21/2010 05/21/2020 Common Stock 17,500 $ 12.76 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/20/2011 05/20/2021 Common Stock 17,500 $ 19.02 I See footnote (2)
Non-Qualified Stock Options (right to buy)These non-qualifie 05/18/2012 05/17/2022 Common Stock 17,500 $ 20.06 I See footnote (2)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
667, L.P.
667 MADISON AVENUE 21ST FLOOR
NEW YORK, NY US 10065
  X      

Signatures

Baker Bros. Advisors, LLC, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing 05/21/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares of common stock of Seattle Genetics Inc. reported herein are held directly by 667, L.P. ("667"), a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC. Baker Bros. Advisors, LLC (the "Adviser") serves as the Investment Adviser to 667. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest. On April 12, 2012, the Adviser, 667 and the general partner of 667 entered into an amended and restated management agreement which gave the Adviser complete and unlimited discretion and authority with respect to 667's investments and voting power over investments. The general partner of 667 relinquished all discretion and authority with respect to 667's investments and voting power over investments. Julian C. Baker and Felix J. Baker each may be deemed to control the Adviser and to indirectly beneficially own the shares beneficially owned by it. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of these securities, except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is the beneficial owner of the above referenced securities for purposes of Section 16 or for any other purpose. The shares reported herein have been previously reported by Felix J. Baker, Julian C. Baker and the Adviser in their own Section 16 reports. In the future, 667 may jointly file Section 16 reports with Julian C. Baker, Felix J. Baker and the Adviser.
(2) These stock options were issued to Felix J. Baker in his capacity as director of Seattle Genetics, Inc. Felix J. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of 667. Felix J. Baker, pursuant to the policies of the Adviser, did not have any right to the pecuniary interest in the stock options issued for his service on the Board. 667, with 14159 and Baker Brothers Life Sciences, L.P. owns an indirect proportionate pecuniary interest in the options issued in connection with Felix J. Baker's service on the Board. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the options issued to Felix J. Baker (i.e. no direct pecuniary interest). The stock options reported herein have been previously reported by Felix J. Baker.
 
Remarks:
Remarks:
Felix J. Baker is a director of Seattle Genetics Inc. (the "Issuer"). For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, 667, L.P. is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.